The purpose of this study is to observe and evaluate the correlation between ctDNA-MRD and the therapeutic effect and prognosis of stage II-IVA operable esophageal squamous cell carcinoma.
Patients with stage II-IVA Esophageal squamous cell carcinoma confirmed by clinical pathological staging;
≥18 years;
Eastern Cooperative Oncology Group performance status score (ECOG PS) is 0 ~ 1 points;
Expected survival time ≥ 6 months;
Patients with other malignant tumors;
Patient had undergone surgery before admission;
Pregnant or lactating women;
Patients with other serious diseases;
Esophageal squamous cell carcinoma patients who were initially diagnosed as stage II-IVA (TNM V8) and planned to undergo radical surgery
Cohort
Prospective
Not listed
Progression-free survival
Evaluation of progression-free survival rate of esophageal squamous cell carcinoma patients with different MRD status during perioperative period
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
